Teva Focuses on Central Nervous System, Respiratory Drugs

Published December 12, 2012

Teva Focuses on Central Nervous System, Respiratory Drugs

Filed under: drug treatment news 2012

Teva Focuses on Central Nervous System, Respiratory Drugs. By David Wainer on December 12, 2012. Tweet; Facebook; LinkedIn; Google Plus; Comments · Email · Print … in the next few years,” Judson Clark, an analyst at Edward Jones & Co. who has a buy …
Read more on Businessweek

Rare Safety Data on Zoledronic Acid Beyond 2 Years

Filed under: drug treatment news 2012

However, there were infusion reactions (6.7%), fatigue (2.6%), and creatinine increases (34.9%; 27% with stage G1 and 2% with stage G2) in the women treated with the bone drug for at least 24 months. "Prolonged treatment with zoledronic acid seems to …
Read more on Medscape

State to receive .3 million in Pfizer's settlement on infection-fighting drug

Filed under: drug treatment news 2012

In addition, the attorneys general said the drug maker engaged in illegal marketing for Lyrica by encouraging its use for the treatment of pain conditions, treatments which weren't approved by the FDA. Most of the state's $ 1.3 million share of the …
Read more on Seattle Post Intelligencer (blog)